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Fusarium spp is an opportunistic fungal pathogen responsible for causing invasive hyalohyphomycosis in immunocompromised patients.
Due to its susceptibility pattern with a remarkable resistance to antifungal agents the treatment failures and mortality rates are high. To
overcome this situation, combination therapy may be considered which must be subjected to in vitro tests.
In vitro activities of amphotericin B, itraconazole, and voriconazole associated with azithromycin, ciprofloxacin, fluvastatin, ibuprofen,
metronidazole, and also the combination of amphotericin B plus rifampin against 23 strains of Fusarium spp. through the checkerboard
technique based on M38-A2 [Clinical and Laboratory Standards Institute (2008). Reference method for broth dilution antifungal
susceptibility testing of filamentous fungi; approved standard, 2nd ed. (CLSI document M38-A2) (ISBN 1-56238-668-9). Wayne, PA: CLSI]
were evaluated.
The best synergistic interactions with amphotericin B were with ibuprofen (43.5%) (FICI [fractional inhibitory concentration index]
range = 0.25–2). Combinations with voriconazole showed synergism, mainly with ciprofloxacin (30.4%) (FICI range = 0.25–3) and
metronidazole (30.4%) (FICI range = 0.1–4); however, all the combinations with itraconazole were indifferent. In general, antagonistic
interactions were not registered.
Our results showed that in vitro synergisms obtained by some combinations studied deserve attention since they were better than those
showed by the antimycotic.
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Fusarium spp. is a well-known opportunistic fungal agent
that can cause important infections in immunocompromised
patients. Commonly, it shows primary resistance to most
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Open access under the Elsevier OA license. which exceed 70% (Boutati and Anaissie, 1997; Nucci and
Anaissie, 2002, 2007; Nucci et al., 2004; Raad et al., 2006).
Due to the susceptibility pattern of Fusarium spp., the
antifungal therapy options are limited. In this scenario, the
combinations of 2 classes of antifungal agents have been
studied in order to search for a better effect based on
synergisms. On the other hand, the activity of combinations
including antifungal plus a nonantimycotic has been
explored for Candida, Cryptococcus, and Aspergillus, but
against Fusarium spp these interactions are unknown and
thus require evaluation. The aim of this study was to evaluate
the susceptibility of different species of Fusarium to
conventional antifungal agents associated with other drug
classes. The non-antifungal agents used in this study were
127T.P. Venturini et al. / Diagnostic Microbiology and Infectious Disease 71 (2011) 126–130selected based on other studies which have reported
synergism in vitro in combination with conventional
antifungal agents against fungi, such as Candida spp.,
Cryptococcus spp., and Aspergillus spp. (Chin et al., 1997;
Clancy and Nguyen, 1998; Clancy et al., 1998; Cury and
Hirschfeld, 1997; Edwards et al., 1980; Fujita and Edwards,
1981; Hughes et al., 1984; Kitahara et al., 1976; Kobayashi
et al., 1974; Kunin, 1996; Medoff, 1983; Pina-Vaz et al.,
2000; Scott et al., 1995; Spader et al., 2009; Stergiopoulou
et al., 2008; Stern, 1978).2. Materials and methods
Twenty-three isolates of Fusarium spp. were studied:
F. chlamydosporum (3), F. oxysporum (6), F. solani (10),
F. solani ATCC 36031 (1), and F. proliferatum (3). These
strains were obtained from different sources, including
blood culture (n = 13), tissue biopsy (n = 5), cornea (n = 3),
and sediment of the dialysate from continuous ambulatory
peritoneal dialysis (n = 1). Isolation and identification of the
isolates were performed by standard microbiological and
molecular techniques. Molecular analyses were performed
to confirm the identity of the Fusarium spp. A DNA
fragment comprising an internal transcribed spacer (ITS)
was amplified using primers ITS1 (5′-TCCGTAGGTGA-
ACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGAT-
ATGC-3′) (O'Donnell et al., 2007). The amplified frag-
ments were sequenced, and the sequences were compared
with DNA sequences of Fusarium obtained from GenBank
whose accession numbers were HQ696899, HQ696900, and
HQ696908 for F. chlamydosporium; HQ696888,
HQ696889, HQ696890, HQ696893, HQ696894, and
HQ696895 for F. oxysporum; HQ696874, HQ696875,
HQ696876, HQ696877, HQ696878, HQ696879,
HQ696880, HQ696881, HQ696882, and HQ696883 for
F. solani; and HQ696886, HQ696887, and GQ149771 for
F. proliferatum.
The antifungal agents amphotericin B (AMB), itracona-
zole (ITZ), and voriconazole (VRZ), as well as non-
antifungal agents, azithromycin (AZM), ciprofloxacin
(CIP), fluvastatin (FVS), ibuprofen (IBP), metronidazole
(MTZ), and rifampicin (RIF), were obtained from their
manufacturers as pure powder. The stock solutions were
prepared in dimethyl sulfoxide, except for FVS, which was
prepared in sterile distilled water. The concentrations of
antifungal agents tested were 0.0625 to 8 μg mL−1 for AMB
and 0.125 to 16 μg mL−1 for ITZ and VRZ; the non-
antifungal agents were tested at concentrations ranging from
0.25 to 32 μg mL−1. The antifungal agents were tested alone
and in association with non-antifungal agents. The in-
teractions evaluated were as follows: AMB + AZM, AMB +
CIP, AMB + FVS, AMB + IBP, AMB + MTZ, AMB + RIF,
VRZ + AZM, VRZ + CIP, VRZ + FVS, VRZ + IBP, VRZ +
MTZ, ITZ + AZM, ITZ + CIP, ITZ + FVS, ITZ + IBP, and
ITZ + MTZ.The susceptibility tests were determined by a microdilu-
tion technique (CLSI M38-A2) (Clinical and Laboratory
Standards Institute, 2008), and Candida parapsilosis ATCC
22019, Candida krusei ATCC 6258, and Aspergillus flavus
ATCC 204304 were included as quality control strains. The
interactions of the drugs, based on the same document, were
evaluated by the chequerboard method (Cuenca-Estrella,
2004), where 50 μL of each drug dilution was combined with
another 50 μL of each dilution of the second drug, and to this
volume was added 100 μL of inoculum in RPMI 1640
medium. The concentration ranges of the antifungal agents
and non-antifungal agents were the same as those used for
the susceptibility testing of each agent alone. The inoculum
preparation was based on CLSI M38-A2 (Clinical and
Laboratory Standards Institute, 2008).
To evaluate the interaction between drugs, the fractional
inhibitory concentration (FIC) was calculated for each agent
by dividing the MIC of each drug in the combination by the
MIC of the drug alone. FIC values were then summed to
determine the fractional inhibitory concentration index
(FICI) resulting from the combination. Synergism was
defined as FICI ≤0.5. Indifference was defined as 0.5 b
FICI ≤ 4, whereas antagonism was defined when FICI was
N4 (Cuenca-Estrella, 2004; Mukherjee et al., 2005).3. Results
ITZ, AZM, CIP, FVS, IBP, MTZ, and RIF when tested
alone showed no activity against Fusarium spp. The
antifungal activity of AMB showed MIC values ranging
from 0.125 to 4.0 μg mL−1. Twenty (87%) of 23 isolates
showed MIC ≤1.0 μg mL−1 for AMB and only 3 isolates
(13%) showed MIC N1.0 μg mL−1. Only 1 isolate of
F. solani and 1 isolate of F. oxysporum required MIC =
4.0 μg mL−1 to AMB.
The susceptibility to VRZ showedMIC≥4.0 μg mL−1 for
87% of isolates and MIC N16.0 μg mL−1 for ITZ for 100% of
the isolates.
All combinations of non-antifungal agents with AMB
showed synergistic interactions, and antagonisms were not
observed in these combinations (Table 1). The best
combinations with AMB were AMB + IBP (43.5%),
followed by AMB + CIP (39.1%). The best combinations
with VRZ were VRZ + CIP (30.4%) and VRZ + MTZ
(30.4%). The concentrations of non-antifungal agents in all
the synergistic interactions were ≤0.25 μg mL−1. Antago-
nistic interactions were not observed. All combinations
with ITZ showed indifferent interactions for 100% of the
Fusarium spp. isolates.4. Discussion
The typical profile of the antifungal susceptibility of
Fusarium spp. is the resistance to most antifungal agents.
Table 1
Number, percentage of synergistic interactions, and FICI range obtained by combinations of amphotericin B and voriconazole with non-antifungal agents against
Fusarium spp.
Fusarium spp. (n) Antifungal
agents
Non-antifungal agents
Number (percentage of synergistic interactions)
FICI range
AZM CIP RIF MTZ IBP FVS
F. chlamydosporum (n = 3) AMB 2 (66.7) 0.25–1 0 (0) 1–2 1 (33.3) 0.1–1 1 (33.3) 0.5–2 0 (0) 1–2 1 (33.3) 0.5–2
F. oxysporum (n = 6) AMB 3 (50) 0.5–1 3 (50) 0.5–2 1 (16.7) 0.25–1 1 (16.7) 0.5–2 0 (0) 1–2 1 (16.7) 0.5–4
F. solani (n = 11) AMB 1 (9.1) 0.5–2 5 (45.5) 0.5–1 4 (36.4) 0.25–2 5 (45.5) 0.5–2 8 (72.7) 0.25–1 4 (36.4) 0.5–2
F. proliferatum (n = 3) AMB 0 (0) 1–2 1 (33.3) 0.5–1 2 (66.7) 0.5–1 1 (33.3) 0.5–1 2 (66.7) 0.5–1 2 (66.7) 0.5–1
Total AMB 6 (26.1) 0.25–2 9 (39.1) 0.5–2 8 (34.8) 0.1–2 8 (34.8) 0.5–2 10 (43.5) 0.25–2 8 (34.8) 0.5–4
F. chlamydosporum (n = 3) VRZ 2 (66.7) 0.5–1 2 (66.7) 0.5–1 (–) 1 (33.3) 0.5–1 1 (33.3) 0.5–1 0 (0) 1
F. oxysporum (n = 6) VRZ 2 (33.3) 0.5–1 4 (66.7) 0.25–1 (–) 4 (66.7) 0.5–1 2 (33.3) 0.5–1 1 (16.7) 0.5–1
F. solani (n = 11) VRZ 1 (9.1) 0.5–3 1 (9.1) 0.5–3 (–) 2 (18.2) 0.1–4 2 (18.2) 0.1–4 2 (18.2) 0.1–1
F. proliferatum (n = 3) VRZ 0 (0) 1–2 0 (0) 1 (–) 0 (0) 1 0 (0) 1 0 (0) 1
Total VRZ 5 (21.7) 0.5–3 7 (30.4) 0.25–3 (–) 7 (30.4) 0.1–4 5 (21.7) 0.1–4 3 (13) 0.1–1
AMB = Amphotericin B; VRZ = voriconazole; AZM = azithromycin; CIP = ciprofloxacin; RIF = rifampicin; MTZ = metronidazole; IBP = ibuprofen; FVS =
fluvastatin; (–) = not performed.
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sensitivity. The susceptibility of F. solani and F. oxysporum
has been studied more than that of other Fusarium species
because they are more prevalent in immunocompromised
patients (Córdoba et al., 2008; Nucci and Anaissie, 2007).
Species such as F. chlamydosporum, F. nygamai,
F. proliferatum, and F. sporotrichoides are rarely reported
in human infections; thus the susceptibility of these species is
almost unknown.
The prognosis of fusariosis in immunocompromised
patients is directly related to the immune status of patients
(Nucci and Anaissie, 2007), with high mortality rates (over
70%) in this population (Raad et al., 2006). Proper treatment
of disseminated infections is still not fully understood. AMB
and VRZ are the most effective drugs; however, numerous
therapeutic failures have been registered (Pujol et al., 1997).
Here, we evaluated the in vitro interactions between
AMB, ITZ, and VRZ with non-antifungal agents (AZM,
CIP, FVS, IBP, and MTZ) as well as the combination
between AMB + RIF against 23 Fusarium spp. isolates.
The combinations with AZM showed synergism with
AMB (26.1%) and VRZ (21.7%) but were indifferent with
ITZ. Clancy and Nguyen (1998) have reported the
synergism AMB + AZM for Fusarium spp.; however, the
combinations with VRZ (VRZ + AZM) and ITZ (ITZ +
AZM) have not been reported until now. AZM has no
antifungal activity due to its inability to penetrate the
membrane of fungal cell. However, the damage caused by
AMB may facilitate the entry of AZM which may inhibit
the synthesis of protein (Clancy and Nguyen, 1998). No
studies emphasizing the combination VRZ + AZM against
Fusarium spp. have been found.
When we tested combinations with CIP, the syner-
gisms showed AMB (39.1%), VRZ (30.4%), and indiffer-
ence with ITZ. Stergiopoulou et al. (2008) reported a
synergism between AMB + CIP against Candida albicansand A. fumigatus as well as between VRZ + CIP against
A. fumigatus. No other studies focusing on these combina-
tions against Fusarium spp. have been performed. CIP has no
intrinsic antifungal activity but it may interact with antifungal
agents and inhibit DNA gyrase (topoisomerase II), which is
abundant in fungi species (Stergiopoulou et al., 2008).
The synergisms observed by the combinations with FVS
were AMB + FVS (34.8%) and VRZ + FVS (13%); the
combinations with ITZ + FVS showed indifference. The
synergisms between FVS with antifungal agents have been
reported by other studies: Chin et al. (1997) reported
synergism between FVS plus fluconazole or ITZ against
Candida spp. and Cryptococcus neoformans. Natesan
et al. (2008) observed that FVS increased the effect of
caspofungin but did not show synergistic interactions with
VRZ or AMB against A. fumigatus. The combinations
AMB + FVS, ITZ + FVS, and VRZ + FVS have not been
tested against Fusarium species yet. The mechanism of
antifungal action of FVS in combination with antifungal
agents is still unclear. It has been hypothesized that the
inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase
could lead to a decrease of ergosterol levels or another
cytosolic precursor of ergosterol required in the fungal cell
membrane synthesis (Nash et al., 2002).
The combination AMB + IBP showed synergism for
43.5% of the Fusarium spp. isolates, which was the highest
rate of synergism observed in this study. The synergism of
the combination VRZ + IBP was 21.7%; however, the
indifference (100%) was the interaction showed by ITZ +
IBP. Scott et al. (1995) and Pina-Vaz et al. (2000) have
reported synergism for the fluconazole + IBP combination
against Candida spp. These authors concluded that high
doses of IBP are fungicidal and directly damage the
cytoplasmatic membrane, whereas at low concentrations
the combination (fluconazole + IBP) is fungistatic and does
not affect the cytoplasmic membrane of the fungi. Another
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efflux induced by IBP. These mechanisms may explain our
results; however, the combinations AMB + IBP, VRZ + IBP,
and ITZ + IBP have not been reported until now.
The associations with MTZ showed synergism for
AMB + MTZ (34.8%) and VRZ + MTZ (30.4%), but the
interaction ITZ + MTZ showed indifference (100%). Cury
and Hirschfeld (1997) reported synergism for the combi-
nation AMB + MTZ against Candida albicans. The
mechanism of interaction between MTZ and antifungal
agents is not well understood. To date, no studies
encompassing combinations between antifungal agents
plus MTZ against Fusarium spp. have been reported.
RIF was combined only with AMB which showed
synergism for 34.8% of Fusarium spp. isolates. Some
studies showed that RIF interacts synergistically in vitro with
AMB against Candida spp., Cryptococcus neoformans, As-
pergillus spp., and Histoplasma capsulatum (Clancy et al.,
1998; Edwards et al., 1980; Fujita and Edwards, 1981;
Hughes et al., 1984; Kitahara et al., 1976; Kobayashi et al.,
1974; Kunin, 1996; Medoff, 1983). According to Stern
(1978), this combination was synergistic for most of the
Fusarium spp. isolates, which was shown by Spader et al.
(2009) who reported high rates of synergism (68.7%) against
Fusarium spp. Guarro et al. (1999) have also reported a
synergism between AMB + RIF against Fusarium solani.
Clancy et al. (1998) suggest that AMB damages the fungal
cell membrane allowing the entry of RIF, which exerts its
antifungal effect by inhibiting the synthesis of RNA.
F. solani and F. oxysporum are the most prevalent Fusar-
ium species and therefore deserve to be emphasized. Among
all the combinations tested, the highest rate of synergism
against F. solani was shown by AMB + IBP (72.7%). For
F. oxysporum, for best results, 2 combinations were obtained:
VRZ + CIP and VRZ + MTZ, both showing 66.7%
synergisms. The plasmatic concentrations of ibuprofen
(61.1 ± 5 μg mL−1), ciprofloxacin (2.5 ± 1 μg mL−1), and
metronidazole (11-14 μg mL−1) (Brunton et al., 2007) are at
least 10 times more elevated than the MIC values observed in
combination with amphotericin B or voriconazole. Consider-
ing that ibuprofen, ciprofloxacin, and metronidazole are well-
known and secure drugs, we believe these synergisms deserve
in vivo studies in order to confirm our findings. If these anti-
Fusarium activities are confirmed, they may be useful in
some refractory cases of fusariosis as salvage therapy.
Based on previous reports, our results confirm that com-
binations between antifungal agents plus non-antifungal
agents may be promising and instigating further studies
focusing on in vivo applications in an experimental Fusarium
infection deserves to be pursued.
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